Conditionnement : 5mg
Demander plus d'informations
Veuillez vous connecter pour utiliser cette fonctionnalité.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
CMX001 is a broad spectrum antiviral agent [1].
CMX001 has been reported to be active in vitro against a broad range of viruses from all five families of dsDNA viruses infecting human with EC50 values of 0.02μM, 0.0004μM, 17μM , 0.045μM and 0.07μM for Adenovirus, Herpesvirus, Papillomavirus, Polyomavirus and Orthopoxvirus, respectively. In addition, CMX001 has been revealed to arrest disease progression by inhibiting viral DNA replication and thereby reducing viral burden. Apart from these, initial studies has been demonstrated the efficacy of CMX001 for pre-exposure and post-exposure prophylaxis in mouse, rabbit, cynomolgus monkeys and human [1].
References:[1]Lanier R1, Trost L, Tippin T, Lampert B, Robertson A, Foster S, Rose M, Painter W, O'Mahony R, Almond M, Painter G.Development of CMX001 for the Treatment of Poxvirus Infections. Viruses. 2010 Dec; 2(12):2740-2762.
Cell lines
Human fetal brain SVG cells
Preparation method
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reacting condition
0.01, 0.03, 0.07, 0.1, and 1 μM, 96 h
Applications
CMX001 caused a dose-dependent decrease in the number of JCV-infected cells during initial infection. In addition, CMX001 treatment resulted in a dose-dependent decrease in the number of JCV genome copies present in infected cells.
Animal models
4-6 week-old female A/Ncr mice
Dosage form
Oral administration, 10 mg/kg on day 0 and 2.5 mg/kg every other-day
Application
Treating mice with CMX001 at a 10 mg/kg dose followed by 2.5 mg/kg doses every other-day for two weeks provided solid protection against mortality and weight loss following an intra-nasal challenge of ectromelia virus.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Jiang Z G, Cohen J, Marshall L J, et al. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures[J]. Antimicrobial agents and chemotherapy, 2010, 54(11): 4723-4732.
[2]. Parker S, Touchette E, Oberle C, et al. Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model[J]. Antiviral research, 2008, 77(1): 39-49.